3Einh(a)upl K,Bousser MG,de Bruijn SF,et al.EFNS guideline on the treatment of cerebral venous and sinus thrombosis[J].Eur J Neurol,2006,13(6):553-559.
6Ferro JM,Canh(a)o P,Siam J,et al.Proguosis of cerebral vein and dural sinus thrombosis:results of the International Study on Cerebral Vein and Dural Sinus Thrombosis(ISCVT)[J].Stroke,2004,35(3):664-670.
7Heller PG,Lev PR,Salim JP,et al.JAK2V617F mutation in platelets from essential thrombocythemia patients:correlation with clinical features and analysis of STAT5 phosphorylation status[J].Eur J Haematol,2006,77(3):210-216.
8Harrison CN,Green AR.Essential thrombecythaemia[J].Best Pract Res Clin Haematol,2006,19(3):439-453.
2Tefferi A,Gilliland DG.Oncogenes in myeloproliferative disorders[J].Cell Cycle,2007,6(5):550-566.
3Saharinen P,Takaluoma K,Silvennoinen O.Regulation of the Jak2tyrosine kinase by its pseudok inase domain[J].Mol Cell Bio,2000,20(10):3387-3395.
4Smith CA,Fan G.The saga of JAK2 mutations and translocations in hematologic.disorders:pathogenesis,diagnostic and therapeutic prospects,and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms[J].Hum Pathol,2008,39:795-810.
5Dalal I,Arpaia E,Dadi H,et al.Cloning and characterization of the human homolog of mouse Jak2[J].Blood,2008,91(3):844-851.
8Baxter EJ,Scott LM,Campbell PJ,et al.Acquired mutation of the tyrosine kinase JAK2 V617F in human myeloproliferative diseases[J].Lancet,2005,365(3):1054-1061.
9Tefferi A,Vardiman JW.Classification and diagnosis of myeloproliferative neoplasms:The 2008 World Health Organization criteria and pointof-care diagnostic algorithms[J].Leukemia,2008,22:114-122.
10Passamonti SM,Biguzzi E,Cazzola M,et al.The JAK2V617F mutation in patients with cerebral venous thrombosis[J].Thromb Haemost,2012,10:998-1003.
